Daily Dosing: The necessity of daily intake might be less convenient for some patients compared to weekly injections
Springer Nature Switzerland AG.
Conclusions Compared with placebo, tirzepatide resulted in statistically significant and clinically meaningful weight reduction, especially in patients without diabetes (with overweight/obesity), with an acceptable safety profile
Stronger combined appetite suppression means the under-eating pattern seen on semaglutide and tirzepatide is a floor of concern, not a ceiling
Sheikh A, Li X, Wen G, Tauqeer Z, Brown W, Malik M
When prescribed for appropriate patients and monitored by a licensed medical provider, weight loss treatments can be safe and effective